Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

• Status: COMPLETED
• Trial end date: 2025-07-22

Summary

This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.

• Phase: PHASE1

Details

• Lead Sponsor: AQILION AB
• Treatments: Suspensions